Facebook
Twitter
LinkedIn
Forward
Virtual Symposium- Challenges and Advances in Long-Term Obesity Management: Interpreting and Applying the Evidence to Patient Care
Nearly 40% of adults in the United States are obese: a number that is expected to rise in the near future. The impacts of obesity are profound, both in terms of increasing cardiometabolic risk as well as exacerbating morbidity and mortality from existing cardiometabolic conditions. During this symposium, expert faculty will discuss the importance of obesity as a disease, its comprehensive management, and the latest advances in pharmacotherapy for long-term obesity treatment.
This activity is part of the Obesity Management Digital Education Hub
Target Audience
This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), registered nurses, nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, dieticians, and other allied health professionals.
Learning Objectives
After completing this activity, the participant should be better able to:
- Identify obesity as a treatable disease and incorporate practical approaches for its screening and diagnosis.
- Review the efficacy and safety of obesity pharmacotherapy in the treatment of patients with obesity.
- Recommend comprehensive treatment strategies, including lifestyle modification and obesity pharmacotherapy, to address overweight and obesity and lower cardiometabolic risk.
Additional Information
| Attachment | Size |
|---|---|
 Peer-to-Peer Obesity Toolkit | 8.35 MB |
Harold E. Bays, MD (Chair)
Medical Director/President
Louisville Metabolic and Atherosclerosis
Research Center, Inc.
Louisville, KY
Dr. Bays discloses the following:
Dr. Bays’ research site has received research grants from Alon Medtech/Epitomee, Amgen, Boehringer Ingelheim, Eli Lilly, Janssen, Johnson and Johnson, Novartis, Novo Nordisk, Pfizer.
Dr. Bays has served as a consultant/advisor for Gelesis.
Dr. Bays has served as a speaker for Novo Nordisk.
Louis J. Aronne, MD
Sanford I. Weill Professor of Metabolic Research
Medical Director, Center for Weight Management & Metabolic Clinical Research
Weill-Cornell Medical College
New York, NY
Dr. Aronne discloses the following:
Dr. Aronne reports receiving consulting fees from/and serving on advisory boards for Eisai, Gelesis, Jamieson Wellness, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Novo Nordisk, Pfizer and Real Appeal; receiving research funding from Aspire Bariatrics, Allurion, Astrazeneca, Eisai, Gelesis, Janssen and Novo Nordisk; having equity interests in Allurion, ERX Pharmaceuticals, Gelesis, Intellihealth Corp, Jamieson Wellness, Myos Corp and Zafgen; and serving on a board of directors for Intellihealth Corp, Jamieson Wellness and Myos Corp.
Karli Burridge, PA-C, MMS, FOMA
Owner, Gaining Health
Glen Ellyn, IL
Ms. Burridge discloses the following:
Owner: Gaining Health
Speaker: Currax
Consultant/ Advisory Board: Novo Nordisk, Bariatric Advantage, Gelesis
ESTIMATED TIME TO COMPLETE ACTIVITY
1 hour
EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from Novo Nordisk.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-22-007-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
CONTINUING DIETICIAN EDUCATION
This program offers 1.0 CPEUs for dieticians.
ABIM MOC CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period January 28, 2022 through January 28, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
Available Credit
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.